Avinger, Inc. announced that it has entered into a Securities Purchase Agreement with new investor, Zylox-Tonbridge Medical Technology Co., Ltd., pursuant to which the Purchaser agreed to purchase the shares of the Company?s common stock, par value $0.001 per share and shares of two new series of the Company?s preferred stock for the aggregate gross proceeds of $15,000,000 on March 4, 2024. The purchaser agreed to purchase in two tranches. Each share of Series F Preferred Stock has a stated value of $1,000 and is initially convertible into approximately 273 shares of Common Stock at a conversion price equal to the Purchase Price, subject to the terms of the Certificate of Designation of Preferences, Rights, and Limitations of the Series F Preferred Stock.
Zylox-Tonbridge Medical Technology Co., Ltd.
Equities
2190
CNE100004JD2
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.72 HKD | +3.88% | -0.19% | -13.83% |
05-09 | Zylox-Tonbridge Medical Technology Co., Ltd. Announces Retirement of Hongze Liang as an Independent Non-Executive Director | CI |
03-22 | Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023 | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.83% | 449M | |
+10.86% | 124B | |
-5.42% | 11.17B | |
+4.17% | 9.17B | |
-21.47% | 4.71B | |
+8.77% | 3.44B | |
-6.03% | 2.88B | |
-12.05% | 2.11B | |
-7.83% | 2.09B | |
-22.84% | 1.8B |
- Stock Market
- Equities
- 2190 Stock
- News Zylox-Tonbridge Medical Technology Co., Ltd.
- Avinger, Inc. announced that it expects to receive $15 million in funding from Zylox-Tonbridge Medical Technology Co., Ltd.